Search
for
Sort by
Research 15
- 41261 Identification of Demographic and Clinical Features Associated with Multi-Biologic Failure in the CorEvitas Psoriasis Registry
- 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- Exploring novel management options for alopecia areata
- Geriatric Dermatologic Therapy
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Consider Cultural Practices and Barriers to Care When Treating Alopecia Areata
- Understanding the Experience of Healthcare Access and Health-Related Impacts among Individuals with Alopecia Areata
- A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Guest Editor's Note
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2